Patient considerations in metastatic colorectal cancer – role of panitumumab

References

• GiustiRMShastriKACohenMHKeeganPPazdurRFDA drug approval summary: panitumumab (Vectibix)Oncologist200712557758317522246
   PubMed Web of Science ®Google Scholar
• KimGPGrotheyATargeting colorectal cancer with human anit-EGFR monoclonal antibodies: focus on panitumumabBiologics20082222322819707356
   PubMedGoogle Scholar
• WilliamsKJLockhartACTargeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumabOnco Targets Ther2009182161170
   Google Scholar
• Vectibix [package insert]Thousand Oaks, CAAmgen, Inc2015 Available from: http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/vectibix/vectibix_pi.ashxAccessed December 27, 2016
   Google Scholar
• SforzaVMartinelliECiardielloFMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerWorld J Gastroenterol201622286345636127605871
   PubMed Web of Science ®Google Scholar
• YangBBLumPChenAPharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumabClin Pharmacokinet2010491172974020923247
   PubMed Web of Science ®Google Scholar
• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteSurveillance, Epidemiology, and End Results ProgramSEER facts and figures. Colorectal Cancer Available from: https://seer.cancer.gov/statfacts/html/colorectal.htmlAccessed December 7, 2016
   Google Scholar
• SchmollHJVan CustemESteinAESMO consensus guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision makingAnn Oncol201223102479251623012255
   PubMed Web of Science ®Google Scholar
• AndréTBoniCNavarroMImproved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the mosaic trialJ Clin Oncol200927193109311619451431
   PubMed Web of Science ®Google Scholar
• Van CustemECervantesAAdamRESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnn Oncol20162781386142227380959
   PubMedGoogle Scholar
• ThirionPMichielsSPignonJPModulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysisJ Clin Oncol200422183766377515365073
   PubMed Web of Science ®Google Scholar
• Meta-analysis Group in CancerPiedboisPRougierPBuyseMEfficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancerClin Oncol1998161301308
   Google Scholar
• National Comprehensive Cancer NetworkNCCN Guidelines: Colon Cancer. Version 2.2017 Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdfAccessed March 23, 2017
   Google Scholar
• Erbitux [package insert]Indianapolis, INEli Lilly and Company2016 Available from: http://pi.lilly.com/us/erbitux-uspi.pdfAccessed December 27, 2016
   Google Scholar
• YewaleCBaradiaDVhoraIPatilSMisraAEpidermal growth factor receptor targeting in cancer: a review of trends and strategiesBiomaterials201334348690870723953842
   PubMed Web of Science ®Google Scholar
• PeetersMKarthausMRiveraFTerweyJHDouillardJYPanitumumab in metastatic colorectal cancer: the importance of tumour RAS statusDrugs201575773174825895463
   PubMedGoogle Scholar
• KobayashiMEndoSHamanoYSuccessful treatment with modified FOLFOX6 and panitumumab in a cecal cancer patient undergoing hemodialysisIntern Med201655212713026781010
   PubMedGoogle Scholar
• BolonesiRMRogersJEShureiqiIA case report-treatment of metastatic colorectal cancer in a patient on hemodialysisJ Gastrointest Cancer201445Suppl 1161165
   PubMedGoogle Scholar
• KrensLLBaasJMde JongFAGuchelaarHJGelderblomHPharmacokinetic of panitumumab in a patient with liver dysfunction: a case reportCancer Chemother Pharmacol201473242943324258455
   PubMedGoogle Scholar
• StephensonJJGregoryCBurrisHAn open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumorsClin Colorectal Cancer200981293719203894
   PubMed Web of Science ®Google Scholar
• WeinerLMBelldegrunARowinskyEUpdated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignanciesProc Am Soc Clin Oncol200523206
   Google Scholar
• MalikIHechtJRPatnaikASafety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)J Clin Oncol200523163520
   Google Scholar
• Van CutsemEPeetersMSienaSOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol200725131658166417470858
   PubMed Web of Science ®Google Scholar
• BerlinJSwansonPHarkerWGBurrisHHechtJRNavaleLPanitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing 10% epidermal growth factor receptor (EGFr)J Clin Oncol20062418S354816877720
   PubMedGoogle Scholar
• MitchellEPHechtJRBarandaJPanitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysisJ Clin Oncol200725Suppl 184082
   Google Scholar
• FakihMWongREfficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancerCurr Oncol201017Suppl 1S3S17
   PubMedGoogle Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol200826101626163418316791
   PubMed Web of Science ®Google Scholar
• PriceTJPeetersMKimTWPanitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT). A randomized, multicenter, open label, non-inferiority phase 3 studyLancet Oncol201415656957924739896
   PubMed Web of Science ®Google Scholar
• PeetersMPriceTJCervantesARandomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerJ Clin Oncol201028314706471320921462
   PubMed Web of Science ®Google Scholar
• HechtJRMitchellEChidiacTA randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Clin Oncol200927567268019114685
   PubMed Web of Science ®Google Scholar
• DouillardJYSienaSCassidyJRandomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJ Clin Oncol201028314697470520921465
   PubMed Web of Science ®Google Scholar
• DouillardJYOlinerKSSienaSPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerN Engl J Med2013369111023103424024839
   PubMed Web of Science ®Google Scholar
• HeinemannVvon WeikersthalLFDeckerTFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialLancet Oncol201415101065107525088940
   PubMed Web of Science ®Google Scholar
• ShankaranVCost Considerations in the evaluation and treatment of colorectal cancerCurr Treat Options Oncol20151684126162432
   PubMedGoogle Scholar
• KircherSMMohindraNNimeiriHCost estimates and economic implications of expanded RAS testing in metastatic colorectal cancerOncologist2015201141825410095
   PubMed Web of Science ®Google Scholar
• TejparSStintzingSCiardielloFPrognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 TrialsJAMA Oncol Epub20161010
   Web of Science ®Google Scholar
• VenookAPNiedzwieckiDInnocentiFImpact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance)J Clin Oncol201634suppl abstr 3504
   Google Scholar
• AllegraCJRumbleRBHamiltonSRExtended RAS gene mutation testing in metastatic colorectal carcinoma to predict response-epidermal growth factor receptor monoclonal antibody therapy: American society of clinical oncology provisional clinical opinion update 2015J Clin Oncol2016342179185
   Google Scholar
• HofheinzRDDeplanqueGKomatsuYRecommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumorsOncologist20162121483149127449521
   PubMedGoogle Scholar
• BurtnessBAnadkatMBastiSNCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancerJ Natl Compr Canc Netw20097Suppl 1S5S2119470276
   PubMed Web of Science ®Google Scholar
• FabbrociniGPanarielloLCaroGCacciapuotiSAcneiform rash induced by EGFR inhibitors: review of the literature and new insightsSkin Appendage Disord201511313727171241
   PubMedGoogle Scholar
• ChanprapaphKVachiramonVRattanakaemakornPEpidermal growth factor receptor inhibitors: a review of cutaneous adverse events and managementDermatol Res Pract2014201473424924723942
   PubMedGoogle Scholar
• MacdonaldJBMacdonaldBGolitzLELoRussoPSekulicACutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membraneJ Am Acad Dermatol201572220321825592338
   PubMed Web of Science ®Google Scholar
• LacoutureMEAnadkatMJBensadounRJClinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated derma-tologic toxicitiesSupport Care Cancer20111981079109521630130
   PubMed Web of Science ®Google Scholar
• LacoutureMEMitchellEPPiperdiBSkin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancerJ Clin Oncol20102881351135720142600
   PubMed Web of Science ®Google Scholar
• Van CutsemETejparSVanbeckevoortDIntrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST studyJ Clin Oncol201230232861286822753904
   PubMed Web of Science ®Google Scholar
• PetrelliFBorgonovoKBarniSThe predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trialsTarget Oncol20138317318123321777
   PubMed Web of Science ®Google Scholar
• KoukakisRGattaFHechmatiGSkin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trialsQual Life Res201625102645265627083443
   PubMed Web of Science ®Google Scholar
• ThalerJKarthausMMineurLSkin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II studyBMC Cancer20121243823020584
   PubMedGoogle Scholar
• MeloskyBLeighlNBRothensteinJSanghaRStewartDPappKManagement of egfr tki-induced dermatologic adverse eventsCurr Oncol201522212313225908911
   PubMed Web of Science ®Google Scholar
• CalifanoRTariqNComptonSExpert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UKDrugs201575121335134826187773
   PubMed Web of Science ®Google Scholar
• CostaATeiparSPrenenHVan CutsemEHypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agentsTarget Oncol20116422723322113391
   PubMed Web of Science ®Google Scholar
• JiangDMDennisKSteinmetzAManagement of epidermal growth factor receptor inhibitor-induced hypomagnesemia. a systematic reviewClin Colorectal Cancer2016153e117e12326961757
   PubMed Web of Science ®Google Scholar
• O’NeilBHAllenRSpigelDRHigh incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic historyJ Clin Oncol200725243644364817704414
   PubMed Web of Science ®Google Scholar
• ChungCHMirakhurBChanECetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactoseN Engl J Med2008358111109111718337601
   PubMed Web of Science ®Google Scholar
• SaifMWPeccerilloJPotterVASuccessful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literatureCancer Chemother Pharmcol200963610171022
   PubMed Web of Science ®Google Scholar
• LangerakARiverGMitchellECheemaPShingMPanitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reportsClin Colorectal Cancer200981495419203897
   PubMedGoogle Scholar